The guidance informs healthcare professionals of best practice around the use and prescribing of valproate (Epilim, Depakote, Convulex, Episenta, Epival, Kentlim, Orlept, Syonell, Valpal and Belvo), which is associated with a significant risk of birth defects and developmental disorders in children born to women who take valproate during pregnancy.
This guidance has been produced on behalf of the Royal College of General Practitioners, Association of British Neurologists and Royal College of Physicians, and endorsed by RCPCH among other professional bodies.
First published in March 2019, the guidance was updated in December 2020, reflecting minor changes made by the MHRA and changes to GMC decision-making guidelines, as well as updated input from all contributing organisations.
You can access the guidance on the below link and downloadable document.